The optimal treatment of true bifurcation lesions not affecting the left main coronary artery is widely debated. Results from randomized studies have shown neutral or worse outcomes with the two-stent technique. Regarding these studies, researchers used first-generation stents and the secondary branches were small. The EBC TWO study compared the provisional stenting strategy against the<a href="https://solaci.org/en/2023/05/29/provisional-stenting-vs-culotte-5-year-results-of-ebc-two/" title="Read more" >...</a>
EuroPCR 2023 | Left Main Coronary Artery Angioplasty: One or Two Stents?
The EBC MAIN LM study randomized 467 patients with severe left main coronary artery (LCA) lesions to receive provisional stenting or a two-sent strategy (Resolute or Onix stent). The two-stent strategy was decided by the operator (culotte, DK-minicrush, T/TAP). The crossover rate from those randomized to provisional stenting was 22%. After a 3-year follow-up, the composite<a href="https://solaci.org/en/2023/05/21/europcr-2023-left-main-coronary-artery-angioplasty-one-or-two-stents/" title="Read more" >...</a>
PICCOLETO-II: Drug-Coated Balloons in Small Vessels
Use of drug-coated balloons vs. drug-eluting stents in small caliber vessels. The constant advancements in coronary device technology have significantly reduced complication rates (such as that of restenosis). However, there are gaps where a high number of undesirable events prevail, such as small vessel disease (SVD), for which, in previous studies up, the rate of<a href="https://solaci.org/en/2023/04/28/piccoleto-ii-drug-coated-balloons-in-small-vessels/" title="Read more" >...</a>
Differences in Events Between MINOCA and MIOCA Patients: Contemporaneous Cohort Analysis
Sex-related MINOCA and MIOCA differences. Several international guidelines recommend invasive treatment after diagnosing an acute coronary syndrome (ACS). The first studies that described acute myocardial infarction (AMI) without obstructive epicardial coronary disease reported a 10% incidence rate. Based on this significant prevalence, it was recommended that this diagnosis be classified as MINOCA for patients who<a href="https://solaci.org/en/2023/04/26/differences-in-events-between-minoca-and-mioca-patients-contemporaneous-cohort-analysis/" title="Read more" >...</a>
Clinical Impact of Coronary Artery Disease on Results After TAVR
Coronary artery disease (CAD) coexists with aortic stenosis in about half the patients who suffer the latter. These patients receiving antiplatelet therapy are at a higher risk of periprocedural bleeding—one of the most frequent complications in patients who undergo transcatheter aortic valve replacement (TAVR). One way of limiting the risk for bleeding is choosing the<a href="https://solaci.org/en/2023/04/17/clinical-impact-of-coronary-artery-disease-on-results-after-tavr/" title="Read more" >...</a>
Is Using Drug-Eluting Balloons and Single Antiplatlelet Therapy Safe for Patients at High Risk for Bleeding Who Undergo Percutaneous Coronary Intervention?
The safety and efficacy of drug-coated balloons (DCB) has been established for the treatment of in-stent restenosis of conventional bare-metal stents (BMS) and drug-eluting stents (DES). Furthermore, these devices are also used to treat de novo coronary lesions, as demonstrated in the BASKET-SMALL 2—where DCBs were non-inferior to stents—and the DEBUT RCT trials—, where DCBs<a href="https://solaci.org/en/2023/02/07/is-using-drug-eluting-balloons-and-single-antiplatlelet-therapy-safe-for-patients-at-high-risk-for-bleeding-who-undergo-percutaneous-coronary-intervention/" title="Read more" >...</a>
Left Main Coronary Artery Percutaneous Coronary Intervention: Evolution and Results over Time
Left main coronary artery percutaneous coronary intervention (LMCA PCI) is a treatment option that is increasingly used in our setting. One of the reasons for choosing this therapeutic strategy is the improvements in devices and techniques. However, the long-term results of LMCA PCI are not well established. The aim of this retrospective study was to<a href="https://solaci.org/en/2023/01/31/left-main-coronary-artery-percutaneous-coronary-intervention-evolution-and-results-over-time/" title="Read more" >...</a>
FRAME-AMI: FFR vs. Angiography of Non-Culprit Vessel in ACS
This study compared fractional flow reserve (FFR) vs. angiography to guide the angioplasty of non-culprit vessels in patients with acute coronary syndrome (ACS) and multivessel disease. Landmark studies such as COMPLETE, COMPARE-ACUTE and DANAMI-3-PRIMULTI have demonstrated the prognostic value of revascularization (after treatment of the artery responsible for the ACS) of non-culprit arteries with respect<a href="https://solaci.org/en/2023/01/25/frame-ami-ffr-vs-angiography-of-non-culprit-vessel-in-acs/" title="Read more" >...</a>
Real-World Revascularization Strategy for Left Main Coronary Artery: Surgery or PCI?
There are many current randomized trials comparing percutaneous coronary intervention (PCI) with myocardial revascularization surgery (MRS) for the treatment of left main coronary artery disease (LMCAD). In the European Society of Cardiology guidelines, PCI is classified as Ia (LMCAD with low-complexity coronary disease) or IIa indication (intermediate complexity), whereas, according to the American Heart Association<a href="https://solaci.org/en/2023/01/11/real-world-revascularization-strategy-for-left-main-coronary-artery-surgery-or-pci/" title="Read more" >...</a>
Interventional cardiology: the most read articles of 2022 in solaci.org
Discover the most read scientific articles on interventional cardiology of 2022 in our website. The FDA Approves Intravascular Lithotripsy for Calcified Lesions The US Food and Drug Administration (FDA) has cleared the shockwave lithotripsy system to treat severely calcified plaque lesions. Is Epinephrine Superior to Adenosine in No-REFLOW? In patients with acute coronary syndrome, no-reflow prevalence is 32%. Different drugs—such as adenosine, verapamil,<a href="https://solaci.org/en/2023/01/05/interventional-cardiology-the-most-read-articles-of-2022-in-solaci-org/" title="Read more" >...</a>